To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies. 56 generic manufacturers and product developers have now signed sublicensing agreements with MPP.
Overview of all licensing and sublicensing agreements
To know more about MPP’s impact
A slide deck highlighting progress of MPP’s generic partners in developing, manufacturing and supplying MPP-licensed medicines, is available. It is updated twice a year (last update: October 24 – data as of June 24)
Interactive map (click here to view full size):
Patent and licensing status: last updated on 1st October 2023. Disclaimer | Product availability data from MPP sublicensees: last updated in March 2025 (data as of 31st December 2024) | Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions
Disclaimer: The information presented on the interactive map below, under the “Patent and licensing status” filter, is sourced from MPP’s patent and licensing database, MedsPaL. Users should NOT consider MedsPaL a complete and authoritative source of patent information, and it is not meant to provide a ‘freedom-to-operate’ analysis. It only provides a snapshot at a point in time, based on the information available to us.
We do not accept any legal responsibility for the accuracy of data. In particular, we do not guarantee it is complete, up to date or fit for specific purposes. Users should undertake additional country search and legal analysis before making any procurement or business decision.
*[WHO-PQ] Prequalification from the World Health Organization (WHO) | **[USFDA] U.S. Food and Drug Administration | ***[ERP] Expert Review Panel hosted by the Quality and Safety of Medicines department of the WHO and making recommendations to the Global Fund. Temporary approval through the ERP, valid for one year, is permitted where WHO-PQ or USFDA approval are not yet available. This does not apply to products under licences with Gilead Sciences (those licences do not accept ERP).
Interactive map:
– Patent and licensing status: last updated on 11 May 2021;
– Product availability data from MPP sublicensees: last updated in March 2022 (data as of 31 December 2021).
Last update of the interactive table in March 2022 (data as of 31 December 2021).
